Prenetics has completed the majority stake acquisition of ACT Genomics to spearhead its entry into to the US$80+ billion global precision oncology market
FDA market authorization advances personalized cancer care in Asia
Clearance sets the stage for continued R&D investment into early detection / liquid biopsy
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.